cisplatin + carboplatin + pemetrexed + gemcitabine + paclitaxel + docetaxel

This combination refers to a specific set of standard-of-care chemotherapy agents—cisplatin, carboplatin, pemetrexed, gemcitabine, paclitaxel, and docetaxel—utilized as the control arm or chemotherapy backbone in clinical research led by Dr. Arvindran A/L Alaga. These agents represent the primary cytotoxic options for the first-line treatment of non-small cell lung cancer (NSCLC). The regimen typically involves a platinum-based agent (cisplatin or carboplatin) paired with a second-generation or third-generation cytotoxic drug (pemetrexed, gemcitabine, or a taxane like paclitaxel or docetaxel). These drugs function through various mechanisms, including DNA cross-linking, inhibition of folate metabolism, and microtubule stabilization, to inhibit tumor cell proliferation. In the context of the Phase III trial NCT05400954, these agents are compared against a combination of low-dose nivolumab and standard chemotherapy.

Brand names

Taxotere